Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 8, Issue 6, Pages 517-525Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.12.49
Keywords
autoinflammation; humanized anti-IL-6 receptor antibody; IL-6; systemic juvenile idiopathic arthritis; tocilizumab
Categories
Ask authors/readers for more resources
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, resulting in short- and long-term disability. It includes a heterogeneous group of diseases, of which systemic JIA is often resistant to treatment. IL-6 plays a significant role in systemic JIA since it is elevated in serum and correlates with disease activity, including joint involvement, acute phase reactants and fever. Blocking the IL-6-induced signal could therefore be an attractive treatment approach. The use of tocilizumab, a humanized anti-IL-6 receptor antibody, for the treatment of systemic JIA is described. The purpose has been to review the controlled clinical trials evaluating the efficacy and safety of tocilizumab for the treatment of systemic JIA. In two Phase III randomized, double-blind controlled studies a rapid and high response rate has been achieved both regarding systemic features and arthritis activity together with a tolerable safety profile in children with systemic JIA refractory to conventional treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available